Amgen is suing Colorado, Maryland is moving forward, and commentary is piling up ...
And a survey of payers reveals some skepticism about CMS' price-setting prowess
And there is less than meets the eye in a new CBO presentation
And Orchard used an ICER assessment in setting the $4.25M price tag for its gene therapy
Plus a link to a great piece about discount rates, for you true wonks
Plus another 340B study shows a way the program can work to actually *help patients*
I said I'd be off, but didn't want to miss the chance to talk Pfizer, Madrigal and ... hockey hair
And Medicare coverage of weight-loss drugs is grabbing headlines following Wegovy's new approval
But there is also an IQVIA report that makes clear the cost of 340B to the average Joe
And why we should celebrate genericization
And I like BI's $35 inhaler pledge, even if I'm not tracking on the mechanics
And there is just an enormous pile of news to get through ...
